An Open-label, Single-arm, Single-center, Investigator-initiated Pilot Study to Investigate the Efficacy, Safety of Immuncell-LC in Combination with Nivolumab (Opdivo®) in Subjects with Advanced or Recurrent Gastric Cancer
Latest Information Update: 05 Oct 2023
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms ILC-IIT-09
- 15 Sep 2021 Status changed from not yet recruiting to recruiting.
- 30 Nov 2020 New trial record